Original title:&nbsp;New-generation drug-eluting stents reduce stent thrombosis and myocardial infarction: a propensity-score-adjusted analysis from the multicenter REAL registry.&nbsp;Reference:&nbsp;Vignali L et al. Cath Cardiovasc Interv. 2014; Epub ahead of print. Compared to the first generation of drug eluting stents (DES), the new generation has a lower long term risk of in-stent thrombosis and acute myocardial infarction<a href="https://solaci.org/en/2014/10/30/lower-rates-of-in-stent-thrombosis-with-the-new-generation-des/" title="Read more" >...</a>

Original title:&nbsp;Three-Year Outcomes After Revascularization With Everolimus-and Sirulimus -Eluting Stents From the SORT OUT IV Trial.&nbsp;Reference:&nbsp;Lisette Okkels Jensen et al. J Am CollCardiolIntv, 2014;7: 840-8. Drug eluting stents (DES) have been shown to safely and effectively reduce restenosis compared to bare-metal stents. While the risk of thrombosis remains a matter of concern when it comes<a href="https://solaci.org/en/2014/08/29/less-definite-thrombosis-with-everolimus-eluting-stents/" title="Read more" >...</a>

Original:&nbsp;Direct drug-eluting Stenting to reduce stent reestenosis (STRESSED).&nbsp;Reference:&nbsp;Wouter S. Remkes et al. J Am Coll Cardiol Intv, 2014;7: 751-8. Direct stenting, without predilation, has been considered a safe and effective technique that reduces procedural time, radiation exposure, contrast material and costs; however, the pertinent studies tested conventional stents only.&nbsp; This study aimed at assessing whether<a href="https://solaci.org/en/2014/08/26/direct-implantation-of-drug-eluting-stents-does-not-reduce-restenosis/" title="Read more" >...</a>